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SUMMARY
The farnesoid X receptor agonist obeticholic acid has been
shown to ameliorate cholestasis in liver disorders. However,
in the context of liver disease secondary to bowel loss,
obeticholic acid administration exacerbated liver injury and
repressed the expression of intestinal farnesoid X receptor
target genes.
BACKGROUND & AIMS: Options for the prevention of short-
bowel syndrome–associated liver disease (SBS-ALDs) are
limited and often ineffective. The farnesoid X receptor (FXR) is
a newly emerging pharmaceutical target and FXR agonists have
been shown to ameliorate cholestasis and metabolic disorders.
The aim of this study was to assess the efﬁcacy of obeticholic
acid (OCA) treatment in preventing SBS-ALDs.
METHODS: Piglets underwent 75% small-bowel resection
(SBS) or sham surgery (sham) and were assigned to either a
daily dose of OCA (2.4 mg/kg/day) or were untreated. Clinical
measures included weight gain and stool studies. Histologic
features were assessed. Ultraperformance liquid chromatog-
raphy tandem mass spectrometry was used to determine bile
acid composition in end point bile and portal serum samples.
Gene expression of key FXR targets was assessed in intestinal
and hepatic tissues via quantitative polymerase chain reaction.
RESULTS: OCA-treated SBS piglets showed decreased stool fat
and altered liver histology when compared with nontreated
SBS piglets. OCA prevented SBS-associated taurine depletion,
however, further analysis of bile and portal serum samples
indicated that OCA did not prevent SBS-associated alterations
in bile acid composition. The expression of FXR target genes
involved in bile acid transport and synthesis increased within
the liver of SBS piglets after OCA administration whereas,
paradoxically, intestinal expression of FXR target genes were
decreased by OCA administration.
CONCLUSIONS: Administration of OCA in SBS reduced fat
malabsorption and altered bile acid composition, but did not
prevent the development of SBS-ALDs. We postulate that exten-
sive small resection impacts the ability of the remnant intestine
to respond to FXR activation. (Cell Mol Gastroenterol Hepatol
2017;4:65–74; http://dx.doi.org/10.1016/j.jcmgh.2017.02.008)
Keywords: Short-Bowel Syndrome; Liver Disease; Intestinal
Failure–Associated Liver Disease; Obeticholic Acid; Bile Acids;
Farnesoid X Receptor.
Short-bowel syndrome (SBS) describes a condition ofmalabsorption and malnutrition resulting from the
loss of absorptive surface area after small-bowel resection.1
The prevention of severe liver disease in patients with SBS
is one of the major challenges in the clinical management
of these complex patients. SBS–associated liver disease
(SBS-ALD) occurs in approximately 65% of infants after
small-bowel resection2 and is the cause of death in 3%–19%
of infants with SBS.3 Despite the high mortality associated
with SBS-ALD, the cause is not well understood and treat-
ment options are limited.
By using a preclinical piglet model of SBS we have
focused our work on uncovering the molecular, metabolic,
and microbial alterations underpinning the development of
SBS-ALD. Recently, we described SBS-ALD–associated al-
terations in bile acid composition associated with disrupted
farnesoid X receptor (FXR) signaling mechanisms.4 FXR is a
member of the nuclear hormone receptor family of tran-
scription factors.5 FXR is highly expressed in the intestine
and liver where it regulates the expression of genes
involved in bile acid synthesis, absorption, and transport,
thereby facilitating the emulsiﬁcation and absorption of
both dietary fats and fat-soluble vitamins, while preventing
the toxic accumulation of bile acids within the liver. Hence,
Abbreviations used in this paper: FXR, farnesoid X receptor; OCA,
obeticholic acid; CDCA, chenodeoxycholic acid; FGF19, ﬁbroblast
growth factor-19; HCA, hyocholic acid; LCA, lithocholic acid; DCA,
deoxycholic acid; HDCA, hyodeoxycholic acid; SBS, short-bowel
syndrome; SBS-ALD, short-bowel syndrome–associated liver disease;
UDCA, ursodeoxycholic acid; UPLC, ultraperformance liquid
chromatography.
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there is increasing interest in the application of FXR agonists
in the treatment of gastrointestinal disease. The most
commonly studied FXR agonist is obeticholic acid (OCA), a
potent semisynthetic analogue of the primary bile acid
chenodeoxycholic acid, which selectively activates FXR.6,7
OCA has shown hepatoprotective effects in patients with
primary biliary cirrhosis,8,9 diabetes-associated nonalco-
holic fatty liver disease,6 and nonalcoholic steaohepatitis.10
A recent report also suggested efﬁcacy in patients with
primary bile acid diarrhea.11
Given the success of OCA administration in the prevention
of liver disease in both mouse models and human disease, we
postulated that administration of OCA to SBS piglets would
prevent the development of SBS-ALD via preservation of bile
acid composition and FXR signaling pathwayswithin the liver
and intestine. Although OCA efﬁcacy has been shown in a
variety of gastrointestinal settings, this study investigated
OCA efﬁcacy performed in the context of reduced bowel
length and associated liver disease.
Materials and Methods
Animals
This study was approved by the Animal Ethics Com-
mittee of the Murdoch Childrens Research Institute. Weaned
female 3-week-old piglets were transported to The Univer-
sity of Melbourne Centre for Animal Biotechnology (Land-
race/large white cross; Aussie Pride Pork, Kialla, Australia)
and acclimatized before surgery. Piglets were housed at a
temperature of 22C with a 12-hour light/dark cycle and fed
a polymeric infant formula diet (Karicare De-Lact; Nutricia,
Macquarie Park, Australia) supplemented to meet the daily
requirements for piglets. The diets were isocaloric and
isonitrogenous among the groups and were administered on
a per-kilogram basis. Water was given twice daily. Piglets
were housed separately throughout the study.
Clinical Assessment and Growth
Piglet weight was measured weekly before feeding. Stool
samples were collected weekly and stool consistency was
scored by the Royal Children’s Hospital Laboratory Services
(Parkville, Australia). The presence of fat globules within the
stool was assessed semiquantitatively and given a score
between 0 and 3.
Experimental Design
Piglets were allocated randomly to untreated or OCA-
treated sham and SBS groups and acclimatized for 1 week
within the animal facility. Piglets then underwent either a
75% proximal small-bowel resection (SBS group) or a
transection and re-anastomosis (sham group) surgery. The
75% small-bowel resection included the removal of the
small bowel from 90 cm distal to the ligament of Treitz to
225 cm proximal to the ileocecal valve. During the sham
procedure, the intestine was transected and re-anastomosed
at a site 225 cm proximal to the ileocecal valve. Piglets
received intramuscular amoxicillin (70 mg/kg; CSL Limited,
Melbourne, Australia) 24 hours before surgery and the day
of surgery. Piglets received amoxicillin and rehydration salts
(Sanoﬁ-Aventis, South Melbourne, Australia) for 3 days after
surgery in line with current clinical practice. Water and
polymeric infant formula diet were re-reintroduced from
the third day after surgery. OCA/0.5% methylcellulose
(kindly provided by Intercept Pharmaceuticals, Inc, New
York, New York) was administered daily via a single gavage
dose of 2.4 mg/kg/day for 14 days from the time of surgery.
The dose rate of 2.4 mg/kg/day was based on the dose rate
of 10 mg/kg/day used in previous murine and rabbit
studies12 that was adjusted to account for piglet metabolism
according to guidelines published by the US Food and Drug
Administration.
Sample Collection
Animals were euthanized 2 weeks after surgery. Portal
plasma and bile samples were obtained on the day they
were killed and frozen at -80C until required. Liver samples
were collected from the right medial lobe and terminal
ileum samples were obtained from a point 7 cm proximal to
the ileocecal valve. Samples were placed in 4% para-
formaldehyde (Australian Biostain Pty Ltd, Traralgon,
Australia), optimal cutting temperature compound, or snap
frozen in liquid nitrogen.
Hepatic Histology
To provide an overviewof changes in hepaticmorphology,
an experienced veterinary pathologist examined H&E-
stained 5-mm liver sections. Alterations in hepatic lobular
structure including the number of hepatic lobules per ﬁeld of
view and hepatic lobule area were measured on size-
standardized, H&E-stained, liver sections using ImageJ soft-
ware (National Institutes of Health, Bethesda, MD).13 Oil Red
O staining14 was performed on frozen optimal cutting tem-
perature–embedded 10-mm liver sections to visualize hepatic
fat accumulation. After staining, a minimum of 10 individual
hepatic lobules were photographed per pig (Leica Bio-
systems, Mount Waverly, Australia) and optical density
measurements were performed using ImageJ software. Re-
sults are expressed as a percentage of Oil Red O staining per
ﬁeld of viewobtained fromaminimumof 10ﬁelds of viewper
pig. Trichrome staining was performed on 4-mm formalin-
ﬁxed liver sections and the slides were scanned at 20
magniﬁcation (Dotslide; Olympus Corporation, Tokyo,
Japan). Changes in endothelial wall thickness were detected
using ImageJ software on a minimum of 10 vessels per pig.
Determination of Bile Acid Composition
Enodogenous bile acid composition and the concentra-
tion of exogenous obeticholic acid was determined in portal
bile. Bile acid standards and bile acid derivative obeticholic
acid were purchased from Sigma-Aldrich Corporation
(St Louis, MO) or Steraloids Inc (Newport, RI). Deuterated
cholic acid (D-2452) and deuterated chenodeoxycholic acid
(D-2772) were purchased from CDN Isotopes, Inc (Pointe-
Claire, Quebec, Canada). High-performance liquid chroma-
tography–grade chemicals were obtained from Fisher
Scientiﬁc (Fair Lawn, NJ). Bile acids were extracted from
portal serum and bile with 50% ice-cold methanol, followed
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by further extraction with acetonitrile (5% NH4OH). Ultra-
performance liquid chromatography tandem mass spec-
trometry (UPLC-MS) was performed on the resultant
supernatant using a modiﬁed method15 and samples were
analyzed on an Acquity UPLC system coupled to an LCT
Premier mass spectrometer (Waters Corporation, Milford,
MA). Analytes were quantiﬁed individually (3 technical
reads per sample) against known bile acid and obeticholic
standard curves. All quantiﬁcations were normalized
relative to internal standards.
RNA Preparation and Quantitative
Polymerase Chain Reaction
RNA was extracted from liver and terminal ileum
epithelium using TRIzol (ThermoFischer Scientiﬁc, Wal-
tham, MA) and RNA (0.1 mg) and reverse-transcribed into
complementary DNA. Primers were designed using the
Roche Universal Probe Library Assay Design Center
(Table 1). Quantitative reverse-transcription polymerase
chain reactions (10 mL) contained 2.5 mL diluted comple-
mentary DNA, 5 mL FastStart TaqMan Probe Master (Roche
Diagnostics, Risch-Rotkreuz, Switzerland), 900 nmol/L of
each primer, and 250 nmol/L of probe mix. All reactions
were performed in triplicate on the LightCycler 480 System
(Roche Diagnostics). The 2-DDCt method16 was used to
calculate the relative changes in gene expression deter-
mined from quantitative reverse-transcription polymerase
chain reaction experiments using either HRPT1 (liver) or
RPL32 (terminal ileum) as a housekeeping gene and relative
to the sham control group.
Protein Detection
Fibroblast growth factor-19 (FGF19) was detected in
portal serum samples obtained at the time the piglets were
killed after an overnight fast using a porcine-speciﬁc FGF19
enzyme-linked immunosorbent assay kit (Mybiosource, Inc,
San Diego, CA).
Statistical Analysis
All authors had access to the data and reviewed and
approved the ﬁnal manuscript. All study results are
reported as means ± SEM. Statistical analysis was per-
formed using 1-way analysis of variance followed by the
Tukey post hoc test (GraphPad Prism Software 6.0, La Jolla,
CA). P values less than .05 were considered statistically
signiﬁcant.
Results
OCA Administration Reduced Fat Malabsorption
but Altered Liver Morphology
Circulating levels of OCA within portal samples were
quantiﬁed via UPLC-MS to conﬁrm OCA uptake in treated
animals. Circulating OCA was not detectable in untreated
sham or SBS piglets. Circulating OCA was conﬁrmed to be of
similar levels in both treated SBS and sham animals
(Figure 1A). SBS piglets showed common clinical manifes-
tations of SBS including failure to gain weight, persistent
diarrhea, and fat malabsorption (Figure 1B–D). OCA treat-
ment did not inﬂuence weight gain or resolve diarrhea in
SBS piglets, however, OCA-treated SBS piglets showed
decreased stool fat, suggestive of improved fat absorption.
OCA treatment has been efﬁcacious in preventing the
development of liver disease in a range of animal models.
Untreated, sham-operated piglets showed normal liver his-
tology when compared with SBS piglets who showed
decreased hepatic lobule area and small clusters of inﬂam-
matory cells together with mild-to-moderate vesicular zone
3 lipidosis (Figure 2). SBS-associated histologic alterations
were observed to be exacerbated by OCA treatment with the
number of hepatic lobules per ﬁeld of view increased, and
conversely hepatic lobule areas decreased in OCA-treated
SBS piglets (Figure 2A). Oil Red O staining was quantiﬁed
as an indication of fat droplet accumulation within the liver.
Levels of fat droplet accumulation did not differ between
untreated and treated sham groups (Figure 2B). Droplet
accumulation was considered mild-to-moderate in SBS pig-
lets and was conﬁned to zone 3 and midzone, with sparing
of the midportal parenchyma. Lipid accumulation was
increased further in SBS piglets after OCA treatment,
Table 1.List of Primer Sequences and Universal ProbeLibrary
Probe Combinations Used in This Study
Primer Sequence 5’ to 3’
UPL
probe
number
CYP7A1 forward
CYP7A1 reverse
AGGGTGACGCCTTGAATTT
GGGTCTCAGGACAAGTTGGA
46
SHP (NR0B2)
forward
SHP reverse
AGTGCTGCCTGGAGTCCTTA
CCTTTCAGGTAGGCGTATTCC
50
MRP2 (ABCC2)
forward
MRP2 reverse
TCTTGGTGACACACAGCATTC
TTCCCACAACCACAATCTCA
60
BSEP (ABCB11)
forward
BSEP reverse
GCCTGACCACGAGCATCT
AGGTCAGTTTCCAACCCTGAT
3
OSTa (SLC51A)
forward
OSTa reverse
CCTGTTTCTCATCCCTGACG
AGCAGCGCTCTCCTCAGA
3
OSTb (SLC51B)
forward
OSTb reverse
CAGGAGCTGCTGGAAGAGAT
GACCATGCTTATAATGACCACCA
37
SULT2A1 forward
SULT2A1 reverse
GCCTCATCAGTTCCCACCT
GCCTTGGACTTGAAGAAAGC
60
FGF19 forward
FGF19 reverse
ACACCATCTGCCCGTCTCT
CCCCTGCCTTTGTACAGC
13
ILBP (FABP6)
forward
ILBP reverse
GCAAGAAGTTCAAGGCCACT
GGTGGTAGTTGGGGCTGTT
77
HPRT1 forward
HPRT1 reverse
CAGTCAACGGGCGATATAAAA
CAACAATCAAGACATTCTTTCCAG
22
RPL32 forward
RPL32 reverse
AACTGGCCATCAGGGTCAC
CACAACTGGAACTCCTGTCTATTC
64
IL, ileal lipid; UPL, universal probelibrary.
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however, these differences were only signiﬁcant in OCA-
treated sham compared with OCA-treated SBS piglets. Ex-
amination of H&E-stained hepatic sections showed evidence
of lymphedema including the presence of capsule swelling,
connective tissue edema, and swollen ﬁbroblasts in
OCA-treated SBS piglets (Figure 2C).
OCA Treatment Prevents the SBS-Associated
Depletion of Taurine but Is Unable to Prevent
Bile Acid Dysmetabolism
Bile samples were analyzed to assess changes in hepatic
bile acid synthesis after enterohepatic recirculation. Low
bile taurine levels were observed in untreated SBS piglets
when compared with sham controls, but these levels
normalized after OCA treatment (Figure 3A). The biliary bile
acid proﬁle of SBS piglets was disturbed signiﬁcantly rela-
tive to that observed in sham controls, with increased levels
of both conjugated and free primary bile acid hyocholic acid
(HCA) and its conjugated precursor chenodeoxycholic acid
(CDCA). Secondary bile acid species resulting from microbe
and hepatic metabolism (conjugated and unconjugated
lithocholic acid [LCA], conjugated deoxycholic acid [DCA],
conjugated hyodeoxycholic acid [HDCA], and conjugated
ursodeoxycholic acid [UDCA]) were decreased in SBS pig-
lets. OCA treatment decreased conjugated CDCA levels in
sham piglets alone, whereas conjugated LCA, DCA, and
HDCA levels in SBS piglets increased, although these levels
remained signiﬁcantly decreased when compared with
sham controls.
Measurement of portal bile acid composition was per-
formed to determine the composition of bile acid in circu-
lation and for transport to the liver. Portal taurine levels
were unchanged by either surgery or OCA treatment
(Figure 3B). Both unconjugated and conjugated HCA levels
were increased substantially and signiﬁcantly in SBS piglets,
Figure 1. Clinical charac-
teristics of untreated and
OCA-treated sham and
SBSpiglets. (A) Portal OCA
levels as measured by
UPLC-MS, (B) weight gain,
(C) stool consistency, and
(D) stool fat score in un-
treated and OCA-treated
sham and SBS piglets.
Means ± SEM, **P < .01,
***P< .001. N¼ 5–6/group.
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whereas unconjugated DCA was almost undetectable and
unconjugated LCA was reduced. SBS piglets had a decrease
in portal conjugated UDCA when compared with sham
controls, consistent with the reduced levels observed in the
biliary bile. Conjugated LCA and HDCA were undetectable in
portal samples from SBS piglets, but HDCA levels increased
with OCA treatment. OCA treatment in SBS piglets resulted
in a signiﬁcant reduction in portal unconjugated HCA levels
when compared with untreated SBS piglets, however, levels
remained signiﬁcantly increased compared with sham
controls.
A Dichotomous Gene Response to OCA
Treatment Between the Intestine and Liver
in SBS
Given our previous ﬁndings of disturbed FXR signaling in
SBS piglets4 and the OCA-induced modulation of bile acid
composition in SBS piglets, we investigated the relative
expression of key intestinal and hepatic FXR target genes
involved in the regulation of bile acid synthesis and trans-
port. Small-bowel resection had no effect on gene expres-
sion levels of FXR targets in either the intestine or the liver
(Figure 4A and B). In the liver, OCA treatment of sham and
SBS piglets resulted in increased MRP2 gene expression,
whereas small heterodimer partner (SHP), bile salt export
pump (BSEP), organic solute transporter beta (OSTb), and
Sulfotransferase Family 2A Member 1 (SULT2A1) were
increased only in OCA-treated SBS piglets when compared
with untreated SBS piglets. Conversely, within the intestine,
gene expression of the FXR targets FGF19, ileal lipid binding
protein, and OSTb were reduced in SBS piglets after OCA
treatment. The ileal hormone FGF19 is secreted into the
portal blood in response to FXR activation and although
levels were increased after small-bowel resection, OCA
treatment did not alter portal FGF19 levels in OCA-treated
sham or SBS piglets (Figure 4C). FXR gene expression was
measured in liver and intestine samples (Figure 4D). FXR
gene expression was increased signiﬁcantly within the liver
of OCA-treated sham piglets and untreated SBS piglets when
Figure 2. OCA treatment exacerbated SBS-associated liver injury. (A) Histologic evidence of fat droplet accumulation was
observed in H&E-stained liver sections of SBS piglets with granulated hepatocytes apparent in OCA-treated SBS piglets (block
arrow; i–ii). (B) Fat droplet accumulation in SBS piglets was conﬁrmed further by Oil Red O staining (i and ii). (C) OCA-treated
SBS piglets also were observed to show evidence of lymphedema including swelling of the capsule, the development
of capsule tags, loose connective tissue around portal structures, and swollen ﬁbroblasts (indicated by arrows). Means ± SEM,
*P < .05 and **P < .01. N ¼ 5–6/group.
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compared with nontreated sham piglets. Hepatic FXR gene
expression was comparable between untreated and OCA-
treated SBS piglets. Within the intestine, FXR gene expres-
sion was comparable between untreated and OCA-treated
sham piglets and between both sham groups and OCA-
treated SBS piglets. In contrast, intestinal FXR gene
expression was 11-fold higher in untreated SBS piglets
when compared with untreated sham piglets.
Discussion
FXR agonists have been implicated in hepatoprotective
functions and show multiple metabolic beneﬁts, however,
accumulating evidence has suggested that the effects of
chronic FXR activation are likely to be scenario-dependent.
Although chronic FXR activation is beneﬁcial in primary
biliary cirrhosis,8 diabetes-associated nonalcoholic fatty
liver disease,6 and nonalcoholic steatohepatitis,10 the
chronic activation of FXR in a perinatal mouse model led to
unexpected partial perinatal lethality and spontaneous liver
toxicity.5 In this study we examined FXR agonist adminis-
tration in a novel pathologic setting: that of liver disease
associated with short-bowel syndrome. Administration of
the FXR agonist OCA to SBS piglets prevented steatorrhea
and normalized bile taurine levels, but did not prevent bile
acid dysmetabolism or the development of SBS-ALD.
Furthermore, although the expression of FXR target genes
was increased in the liver of SBS piglets treated with OCA,
paradoxically the expression of FXR target genes in the in-
testine was decreased.
OCA treatment was effective in reducing fat malabsorp-
tion, which may offer clinical beneﬁt in patients with SBS.
Fat malabsorption is one of the most troublesome symp-
toms experienced by patients with SBS. Not only does it
cause discomfort, but also results in a waste of ingested
energy and fat-soluble vitamins, and can be a key contrib-
utor to malnutrition experienced by patients with SBS. A
treatment that enhances absorptive status has the potential
to convert a parenteral nutrition–dependent SBS patient to
enteral independence. However, clinical beneﬁt provided by
OCA treatment on enhancing intestinal fat absorption is
outweighed by the impact of increased hepatic fat accu-
mulation and lymphedema observed after OCA treatment.
The results from our study are consistent with a study in
patients with secondary bile acid diarrhea after extensive
intestinal resection.11 We were unable to replicate the re-
sults described in patients with primary bile acid diarrhea,
in whom OCA administration improved stool frequency and
form, and stimulated FGF19 secretion.11 Because taurine
promotes bile ﬂow and biliary conjugation, it is possible that
prevention of low biliary taurine levels resulting from OCA
treatment in SBS may reduce the risk of development of
SBS-ALD. OCA treatment also partially reversed distur-
bances in levels of conjugated bile acids and the portal bile
acid transporter BSEP in SBS piglets. Low levels of conju-
gated bile acids have been associated with malnutrition, but
whether this may contribute to malnutrition experienced in
patients with SBS-ALD is not known.17 The prevention or
modiﬁcation of disturbances in the bile acid proﬁle and
biliary taurine levels, and a reduction in fat malabsorption
after OCA treatment, may have the potential to offer clinical
beneﬁt to patients with SBS.
OCA treatment has been effective in preventing liver dis-
ease in a range of animal models, including those mimicking
cholestasis,18 steatosis,19 and cirrhosis.20 However, in the
current study we report evidence of hepatic lipidosis, hepatic
metabolite toxicity, and extensive lymphedema within the
Figure 3. SBS-associated alterations in bile acid composition were not prevented by OCA treatment. Concentration of
taurine, unconjugated bile acid species, and conjugated bile acid species with (A) bile and (B) portal samples. Means ± SEM,
*P < .05, **P < .01, ***P < .001. N ¼ 5–6/group. BA, bile acid; CA, cholic acid.
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Figure 4. OCA treatment resulted in increased gene expression of FXR targets within the liver, but paradoxically
a decrease in FXR target gene expression in the intestine of SBS piglets. The relative gene expression of FXR gene
targets within the (A) liver and (B) intestine from untreated and OCA-treated sham and SBS piglets, and (C) portal FGF19
concentration. Means ± SEM, *P < .05, **P < .01, ***P < .001. N ¼ 5–6/group. BA, bile acid.
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Figure 5. The potential inﬂuence of SBS-associated microbial dysbiosis on OCA efﬁcacy within the intestine. BA, bile
acid; CYP7A1, cytochrome P450 7A1.
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liver of SBS piglets treated with OCA. A major difference be-
tween previous studies and this study is the underlying eti-
ology of the liver disease. Prior studies have examined OCA
treatment in models in which liver disease has been intro-
duced by a chemical, surgical, or genetic cause with an intact
intestine. In contrast, in this study, liver disease has occurred
in the setting of a signiﬁcant disruption of the gut–liver axis
after the removal of 75% of the small intestine. Suppressed
FXR activation within the remnant intestine of SBS piglets
treated with OCA may explain the liver injury observed.
Although hepatic and intestinal FXR traditionally have been
considered to cooperate to down-regulate CYP7A1 expres-
sion, evidence emerging from tissue-speciﬁc knockout and
transgenic FXR activation models suggest that it is intestinal
FXR activation that protects the liver from bile acid–
associated damage. These studies have shown that intestinal
FXR activation confers protection against hepatocarcino-
genesis21 and intrahepatic and extrahepatic cholestasis22 via
restoration of the Fgf15/Fibroblast Growth Factor Receptor 4
enterohepatic signaling axis and consequent up-regulation of
bile acid detoxiﬁcation and efﬂux pathways. Conversely,
Modica et al22 have suggested that activation of the canalic-
ular bile acid transport systems by hepatic FXR alone is un-
likely to provide hepatoprotection. This is consistent with the
current study in which hepatic FXR targets were activated in
SBS piglets treated with OCA, but failed to prevent liver dis-
ease. In the setting of SBS, intestinal FXR activation would be
hampered further by removal of a large portion of FXR con-
taining cells in the resected intestine. Hence, we postulate that
after extensive small-bowel resection, OCA is unable to
generate sufﬁcient FXR/FGF19 signaling to prevent SBS-ALD.
FXR activation also is inﬂuenced by the composition of
the bile acid pool.23 In this study we observed a signiﬁcant
disturbance in bile acid composition in SBS piglets. This was
characterized by an increase in the primary bile acid HCA
within the gallbladder and is consistent with previous
ﬁndings from our group.4 HCA is a hydrophilic bile acid
derived from CDCA in the liver as a means of bile acid
detoxiﬁcation,24 and the increase in HCA observed in our
study may reﬂect an adaptive response to bile acid dys-
metabolism associated with SBS. However, OCA treatment
failed to normalize HCA levels in our model and levels of
this bile acid remained signiﬁcantly higher than sham con-
trols despite OCA administration. We also observed
decreases in the secondary/tertiary bile acids LCA, DCA,
HDCA, and UDCA associated with SBS. The conversion of
primary to secondary/tertiary bile acids is performed by the
colonic microbiota, therefore these changes likely reﬂect
SBS-associated microbial dysbiosis, as has been reported
previously in this model.25 Shifts in the secondary bile acid
pool may be physiologically relevant because these bile
acids are signiﬁcant agonists (DCA and LCA) or antagonists
(UDCA) of FXR and also inﬂuence other host bile acid
receptors.26 After OCA treatment of SBS piglets, signiﬁcant
improvements in HDCA and LCA levels were observed in
systemic bile acid proﬁles (both gallbladder and portal
serum) despite a reduction in the expression of intestinal
bile acid transport systems. It is plausible that OCA treat-
ment impacts the intestinal microbiota and subsequently
the secondary bile acid pool. This hypothesis is supported
by ﬁndings from a murine model of high-fat diet–induced
nonalcoholic fatty liver disease, for which antibiotic treat-
ment altered bile acid composition and inhibited FXR
signaling in the ileum, but not in the liver.27 Similarly,
altering microbial composition via probiotic administra-
tion28 or administration of a high-fat diet29,30 is associated
with reduced activity of the FXR/FGF15 signaling axis.
Further studies are required to conﬁrm if the disturbed
intestinal FXR response observed in SBS piglets in response
to OCA is owing to microbial dysbiosis and consequent bile
acid dysmetabolism or owing to alternative activation of
CYP3A4, which may impact on bile acid metabolism.
In conclusion, this study assessed the impact of treat-
ment with OCA, an FXR agonist, on the development of
SBS-ALD in a preclinical model of SBS. Importantly, we
have shown that small-bowel resection signiﬁcantly ham-
pers the intestinal response to OCA, but not the hepatic
response. Our results suggest that there are fewer
intestinal-based bile acid targets and/or alterations in the
resident microbiota4,25 after extensive resection of the
small intestine and that this inﬂuences the ability of the
intestine to respond to FXR activation by OCA (Figure 5).
Despite a lack of FXR activation by OCA among the intes-
tinal target genes studied, there was an up-regulation of
hepatic FXR target genes, including those involved in
limiting bile acid synthesis and facilitating bile acid
transport, but this failed to prevent the development of
SBS-ALD. Although there may be clinical beneﬁt of OCA on
reducing fat malabsorption, it did not prevent the devel-
opment of SBS-ALD, thereby limiting the potential thera-
peutic beneﬁt of OCA in patients with SBS.
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